Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the ...

The U.S. equity market has been anything but calm in 2025, as several factors, including persistent trade tensions, rising ...

Key Points Amgen offers an attractive dividend and significant upside potential. Vertex Pharmaceuticals is a great biotech ...

Vertex is already looking beyond the triple therapy concept, towards a Gene Editing mRNA drug, which it says could help the entire global population of CF patients, which is up to 75,000 patients ...

But NICE rejected Vertex’s CF latest drug Orkambi for routine NHS funding in final guidance published in July 2016, saying the drug’s £104,000 per year price tag was too expensive.

Two great examples are Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) and Vertex Pharmaceuticals (NASDAQ: VRTX). Warren ...

Princeton University awarded honorary degrees to Omar M. Yaghi, Daniel Chee Tsui, Nancy Weiss Malkiel, Joshua ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Reshma Kewalramani, Bela Bajaria, Revathi Advaithi and Meena Lakdawala Flynn among women at the top of the global business ...

Five Indian-origin women and an Indian woman have been named in Fortune’s 2025 Most Powerful Women list. The list is topped ...

UBS analyst Eliana Merle reaffirmed a Buy rating and a $582 price target for Vertex Pharmaceuticals, praising the adoption of ...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...